Matrisome Bio

Matrisome Bio is developing a first-in-class therapeutic platform that targets the extracellular matrix (ECM), a universal and stable feature of solid tumors and metastases, to deliver radiopharmaceuticals, ADCs, and other payloads with high precision. The company's core technology involves a proprietary toolbox of ECM-specific nanobody binders designed to create a persistent drug depot at the disease site, potentially offering a superior therapeutic index across a broad range of solid tumors. Led by a team with deep expertise in oncology, ECM biology, and drug development, the seed-stage startup is advancing its lead ECM-targeted radiopharmaceutical program while building a pipeline for other indications. Matrisome Bio's approach addresses a major unmet need in metastatic cancers, where traditional therapies often fail due to tumor evolution and heterogeneity.

Proprietary platform for engineering nanobody-based binders that target disease-specific components of the extracellular matrix (ECM). The platform is payload-agnostic, enabling creation of targeted radiopharmaceuticals, antibody-drug conjugates (ADCs), and other therapeutics that convert the ECM into a high-retention drug depot.

Competition includes companies developing therapies against specific ECM proteins (e.g., tenascin-C) and broader tumor microenvironment targets. Matrisome Bio's differentiation lies in its focused ECM proteomics approach, proprietary nanobody toolbox, and pan-tumor targeting strategy within the rapidly growing and competitive radiopharmaceutical and ADC sectors.